Apalutamide

Active substance

apalutamide

Holder

Janssen-Cilag NV

Status

Running

Indication

In combination with androgen deprivation therapy (ADT) for the treatment of adult patients having castration resistant prostate cancer with PSADT ≤ 10 months and no detected metastases using imaging as per physician’s clinical practice

Public documents

Approbation

Information for the patient

Informed consent

Last update

24/07/2018

Last updated on 24/07/2018